CSF3 and plasma cell myeloma: The present single-center analysis demonstrates that the addition of Plerixafor to G-CSF in so-called ‘poor mobilizers’ according to its labeled indication permitted 92% of all myeloma and lymphoma patients requiring ASCT, either as part of their frontline treatment or as salvage treatment for chemo-sensitive relapse in order to prolong PFS and OS, were able to be successfully mobilized to guarantee prompt engraftment after transplant.